C12Y 307/01003
Kynureninase
Official title: Kynureninase (3.7.1.3)
C12Y307/01003 (Kynureninase) appears on 11 US grants and 20 published applications in this corpus.
Search patents in C12Y- Granted patents
- 11
- Published applications
- 20
- Assignees
- 7
- Inventors
- 29
- Latest grant
- 28 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2015 | 0 | 1 |
| 2016 | 0 | 1 |
| 2017 | 1 | 2 |
| 2018 | 1 | 0 |
| 2019 | 0 | 5 |
| 2020 | 1 | 1 |
| 2021 | 1 | 4 |
| 2022 | 2 | 3 |
| 2023 | 2 | 2 |
| 2024 | 1 | 1 |
| 2025 | 0 | 0 |
| 2026 | 2 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Pegylated kynureninase enzymes and uses thereof for the treatment of cancer28 Jul 2026US 12,692,485 B2Board of Regents, The University of Texas System
- Administration of kynurenine depleting enzymes for tumor therapy14 Jul 2026US 12,680,089 B2Board of Regents, The University of Texas System
- Human Kynureninase enzymes and uses thereof19 Nov 2024US 12,144,828 B2Board of Regents, The University of Texas System
- Human kynureninase enzymes and uses thereof16 May 2023US 11,648,272 B2Board of Regents, The University of Texas System
- Human kynureninase enzyme variants having improved pharmacological properties3 Jan 2023US 11,542,486 B2Board of Regents, The University of Texas System
- Administration of kynurenine depleting enzymes for tumor therapy21 Mar 2024US 2024/0091258 A1Board of Regents, The University of Texas System
- Human kynureninase enzymes and uses thereof21 Dec 2023US 2023/0405049 A1Board of Regents, The University of Texas System
- Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells20 Jul 2023US 2023/0226122 A1Synlogic Operating Company, Inc.
- Administration of kynurenine depleting enzymes for tumor therapy1 Sep 2022US 2022/0275099 A1Board of Regents, The University of Texas System
- Cell24 Feb 2022US 2022/0056407 A1Autolus Limited
Most cited
By later US patents
- Administration of kynurenine depleting enzymes for tumor therapy19US 9,808,486 B2Board of Regents, The University of Texas System · 2017
- Administration of kynurenine depleting enzymes for tumor therapy9US 9,975,959 B2Board of Regents, The University of Texas System · 2018
- Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells7US 11,471,494 B2Synlogic Operating Company, Inc. · 2022
- Administration of kynurenine depleting enzymes for tumor therapy6US 10,772,913 B2Board of Regents, The University of Texas System · 2020
- Administration of kynurenine depleting enzymes for tumor therapy5US 11,168,142 B2Board of Regents, The University of Texas System · 2021